modelR01AB07
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Oxymetazoline | |
| ATC code: | R01AB07 | route: | intranasal |
| compartments: | 1 | |
| dosage: | 0.05 | mg |
| volume of distribution: | 18.7 | L |
| clearance: | 12.7 | L/hr/kg |
| other parameters in model implementation | ||
Oxymetazoline is a direct-acting alpha-adrenergic agonist primarily used as a topical decongestant for temporary relief of nasal congestion due to colds, allergies, or sinusitis. It is commonly found in over-the-counter nasal spray products. Oxymetazoline is approved and widely used today for short-term relief.
Pharmacokinetics
Pharmacokinetic parameters for oxymetazoline after intranasal administration in healthy adult volunteers. No population-specific differences (sex, age, or disease conditions) were reported.
References
Cacek, AT, et al., & Gopalakrishnan, M (2017). Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers. Journal of clinical pharmacology 57(2) 247–254. DOI:10.1002/jcph.799 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27436060
Kaessner, N, et al., & Lahu, G (2012). Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain. International journal of clinical pharmacology and therapeutics 50(9) 665–677. DOI:10.5414/CP201737 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22784611
Cartabuke, RS, et al., & Tobias, JD (2019). Hemodynamic and pharmacokinetic analysis of oxymetazoline use during nasal surgery in children. The Laryngoscope 129(12) 2775–2781. DOI:10.1002/lary.27760 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30786035
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)